Bayer Cipro Anthrax Prophylaxis Safety Data Will Be Gathered By CDC
Executive Summary
Bayer will provide tracking data on the use of Cipro (ciprofloxacin) for post-exposure prophylaxis to FDA in accordance with its post-marketing commitments for the product
You may also be interested in...
Animal Efficacy Rule Will Be “Flexible” About Species Needed – CBER’s Zoon
FDA will exercise more flexibility in the number of animal species required for testing before approval of counter-terrorism products under the final animal efficacy rule, Center for Biologics Evaluation & Research Director Kathy Zoon, PhD, said
Animal Efficacy Rule Will Be “Flexible” About Species Needed – CBER’s Zoon
FDA will exercise more flexibility in the number of animal species required for testing before approval of counter-terrorism products under the final animal efficacy rule, Center for Biologics Evaluation & Research Director Kathy Zoon, PhD, said
Anthrax Post-Exposure Drugs Need Extensive Marketing History – Draft Guidance
Drugs should have broad postmarketing experience before sponsors pursue an indication for post-exposure anthrax, a draft guidance from FDA's Center for Drug Evaluation & Research states